Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE
Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE
Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>KCE</strong> Reports 133 Special Solidarity Fund 89<br />
8.3.6 Sufficient expertise at SSF level<br />
The interviewed physicians in particular question if the expertise at the level of the<br />
College of medical directors is sufficient. The variety and rareness of the<br />
diseases/indications makes the assessment by the same panel of “experts” extremely<br />
difficult. One cannot expect them to have all necessary knowledge on all cases<br />
submitted. Although the possibility of consulting external experts by the SSF College<br />
exists, until today this is rarely used. There is however representation of the Drug<br />
Reimbursement Commission in the College of medical directors.<br />
The SSF leading medical officer stressed that the quality of prescriptions, the medical<br />
files and the evi<strong>de</strong>nce is often insufficient. This hampers a proper assessment of the case<br />
at stake by the members of the College.<br />
8.3.7 Appeal<br />
If the patient disagrees with the <strong>de</strong>cisions of the SSF, he/she can launch an appeal to the<br />
competent labour court. Patient organisations state that most patients are not aware of<br />
the appeal procedure or judge it as heavy. The judgments of the labour court are not<br />
systematically monitored by the SSF and do not serve as gui<strong>de</strong>lines for future <strong>de</strong>cisions<br />
on individual cases. Similar cases are not reconsi<strong>de</strong>red or reviewed by the SSF. This is<br />
not so surprising since there is no continuity and uniformity in the interpretation of<br />
some of the eligibility criteria by the courts. A fundamental criticism is that the<br />
expertise at court level is often not sufficient to judge on the mostly very specific<br />
medical issues. One could envisage installing a proper appeal procedure at SSF or<br />
NIHDI level, although legally all disputes regarding the legislation on the compulsory<br />
health care insurance fall within the competence of the labour courts. Installing such an<br />
appeal procedure does not completely solve the issue of ina<strong>de</strong>quate expertise because<br />
of the variety of medical domains. External experts could however be implied.<br />
8.4 EXPLORATION OF (COMPARABLE) SAFETY NETS IN A<br />
SELECTION OF FOREIGN COUNTRIES<br />
No mirror system comparable to the SSF was found in the studied countries. There are<br />
however interesting mechanisms aiming at the management of rare diseases and the<br />
early access to new drugs. A comparison of the reimbursement of a selection of<br />
products reimbursed by the SSF reveals that some of these products are not<br />
reimbursed in the studies countries.<br />
8.4.1 Early access system to new drugs<br />
The notion of “new drug” is consi<strong>de</strong>red as new for a particular indication which implies<br />
that off label use is also consi<strong>de</strong>red. Early access to new drugs is most often during the<br />
third phase of the clinical trial and when its safety and efficacy are strongly assumed.<br />
France and Spain have implemented an early access system. In France, temporary<br />
authorisations (ATU) allows the use of drugs, outsi<strong>de</strong> of the framework of clinical trials,<br />
without Marketing authorisation (MA) in France, w<strong>het</strong>her they benefit or not from a<br />
MA abroad. Solely drugs that are used for the treatment of serious or rare diseases, for<br />
which there is no other treatment available and cost-benefit analysis of the treatment<br />
was conducted, with a positive result are eligible for ATU. Off-label use of drugs is not<br />
eligible for reimbursement. The authorisation can be granted by AFSSAPS for use at<br />
individual patient level (at the request of the prescribing physician) or homogeneous<br />
group (cohort) level (at the request of the pharmaceutical firm) in a very short time<br />
laps. For cohort ATU a temporary use authorisation must be accompanied by a<br />
simultaneous <strong>de</strong>mand for a MA or an intention to file an MA dossier in the near future.<br />
Moreover cohort ATU is subordinated to the implementation of a protocol for<br />
therapeutic use and information collection. For nominative ATU, the agency notably<br />
relies on a dossier on quality, efficacy and safety of the medicinal product supplied by<br />
the pharmaceutical company at its request and, if necessary, by the ATU applicant. In<br />
France, drugs used at hospital level are integrated in the hospital budget.